Anti-V2R/ AVPR2/ ADHR monoclonal antibody
Anti-V2R/ AVPR2/ ADHR antibody for FACS & in-vivo assay
Go to V2R/AVPR2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T66237-Ab-1/ GM-Tg-hg-T66237-Ab-2 | Anti-Human V2R/AVPR2 monoclonal antibody | Human |
GM-Tg-rg-T66237-Ab-1/ GM-Tg-rg-T66237-Ab-2 | Anti-Rat V2R/AVPR2 monoclonal antibody | Rat |
GM-Tg-mg-T66237-Ab-1/ GM-Tg-mg-T66237-Ab-2 | Anti-Mouse V2R/AVPR2 monoclonal antibody | Mouse |
GM-Tg-cynog-T66237-Ab-1/ GM-Tg-cynog-T66237-Ab-2 | Anti-Cynomolgus/ Rhesus macaque V2R/AVPR2 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T66237-Ab-1/ GM-Tg-felg-T66237-Ab-2 | Anti-Feline V2R/AVPR2 monoclonal antibody | Feline |
GM-Tg-cang-T66237-Ab-1/ GM-Tg-cang-T66237-Ab-2 | Anti-Canine V2R/AVPR2 monoclonal antibody | Canine |
GM-Tg-bovg-T66237-Ab-1/ GM-Tg-bovg-T66237-Ab-2 | Anti-Bovine V2R/AVPR2 monoclonal antibody | Bovine |
GM-Tg-equg-T66237-Ab-1/ GM-Tg-equg-T66237-Ab-2 | Anti-Equine V2R/AVPR2 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T66237-Ab-1/ GM-Tg-hg-T66237-Ab-2; GM-Tg-rg-T66237-Ab-1/ GM-Tg-rg-T66237-Ab-2; GM-Tg-mg-T66237-Ab-1/ GM-Tg-mg-T66237-Ab-2; GM-Tg-cynog-T66237-Ab-1/ GM-Tg-cynog-T66237-Ab-2; GM-Tg-felg-T66237-Ab-1/ GM-Tg-felg-T66237-Ab-2; GM-Tg-cang-T66237-Ab-1/ GM-Tg-cang-T66237-Ab-2; GM-Tg-bovg-T66237-Ab-1/ GM-Tg-bovg-T66237-Ab-2; GM-Tg-equg-T66237-Ab-1/ GM-Tg-equg-T66237-Ab-2 |
Products Name | Anti-V2R/AVPR2 monoclonal antibody |
Format | mab |
Target Name | V2R |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-V2R benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species V2R/ AVPR2/ ADHR VLP (virus-like particle) (Products Developing) |
ORF Viral Vector | vGMLP001455 | human AVPR2 Lentivirus particle |
ORF Viral Vector | pGMLP001455 | human AVPR2 Lentivirus plasmid |
Target information
Target ID | GM-T66237 |
Target Name | V2R |
Gene ID | 554,12000,25108,697763,403804,101082135,281642,100059066 |
Gene Symbol and Synonyms | ADHR,AVPR2,DI1,DIR,DIR3,ND1,NDI,NDI1,V2R,VPV2R |
Uniprot Accession | P30518,Q00788,O77808,P48044 |
Uniprot Entry Name | V2R_HUMAN,V2R_RAT,V2R_CANLF,V2R_BOVIN |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target |
Disease | N/A |
Gene Ensembl | ENSG00000126895 |
Target Classification | GPCR |
The target: V2R, gene name: AVPR2, also named as ADHR, DI1, DIR, DIR3, NDI, V2R. This gene encodes the vasopressin receptor, type 2, also known as the V2 receptor, which belongs to the seven-transmembrane-domain G protein-coupled receptor (GPCR) superfamily, and couples to Gs thus stimulating adenylate cyclase. The subfamily that includes the V2 receptor, the V1a and V1b vasopressin receptors, the oxytocin receptor, and isotocin and mesotocin receptors in non-mammals, is well conserved, though several members signal via other G proteins. All bind similar cyclic nonapeptide hormones. The V2 receptor is expressed in the kidney tubule, predominantly in the distal convoluted tubule and collecting ducts, where its primary property is to respond to the pituitary hormone arginine vasopressin (AVP) by stimulating mechanisms that concentrate the urine and maintain water homeostasis in the organism. When the function of this gene is lost, the disease Nephrogenic Diabetes Insipidus (NDI) results. The V2 receptor is also expressed outside the kidney although its tissue localization is uncertain. When these 'extrarenal receptors' are stimulated by infusion of a V2 selective agonist (dDAVP), a variety of clotting factors are released into the bloodstream. The physiologic importance of this property is not known - its absence does not appear to be detrimental in NDI patients. The gene expression has also been described in fetal lung tissue and lung cancer associated with alternative splicing. [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.